BAY-3389934 is a potent, orally active dual inhibitor of coagulation factors Xa and IIa (thrombin), developed by Bayer as a novel oral anticoagulant (NOAC) candidate. In biochemical assays, BAY-3389934 exhibited high affinity for both targets, with IC₅₀ values in the low nanomolar range—approximately 1.1 nM for factor Xa and 1.3 nM for thrombin (factor IIa). In human plasma clotting assays, it effectively prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), indicating functional anticoagulant activity. In preclinical animal models, BAY-3389934 demonstrated robust oral bioavailability, a predictable pharmacokinetic profile, and dose-dependent antithrombotic effects without significantly increasing bleeding risk compared to standard anticoagulants like rivaroxaban or dabigatran. Its dual-target mechanism is designed to provide more comprehensive coagulation inhibition, potentially reducing thrombosis recurrence and resistance..
MedKoo Cat#: 128936
Name: BAY-3389934
CAS#: 2915316-40-2
Chemical Formula: C26H30ClN5O7S2
Exact Mass: 623.1275
Molecular Weight: 624.12
Elemental Analysis: C, 50.04; H, 4.85; Cl, 5.68; N, 11.22; O, 17.94; S, 10.27
The following data is based on the product molecular weight 624.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
